Global Radioligand Therapy Market Report 2025

Item added to cart!

Published : December 2025

Pages : 250

Format : PDF

Delivery Time : 2-3 Business Days

Report Price : $4490.00 $3367.00

Purchase This Report Download Sample PDF

Purchase This Report

Radioligand Therapy Global Market Report 2025

Name: Radioligand Therapy Global Market Report 2025
Brand: The Business Research Company
Price: 4490.00 USD
Availability: InStock

By Type Of Radioligand (Alpha Emitters, Beta Emitters, Auger Emitters, Combined Emissions ), By Molecular Target (Hormone Receptors, Growth Factor Receptors, Antigen Tumor Markers, Other Molecular Targets), By Route Of Administration (Intravenous (IV), Intramuscular (IM), Subcutaneous, Oral ), By Application (Oncology, Cardiovascular Disorders, Neurological Disorders, Infectious Diseases), By End-User (Hospitals, Diagnostic Laboratories, Research Institutions, Home Care Settings) - Market Size, Trends, And Global Forecast 2025-2034

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

Radioligand Therapy Market Overview

• Radioligand Therapy market size has reached to $6.01 billion in 2024

• Expected to grow to $9.77 billion in 2029 at a compound annual growth rate (CAGR) of 10.2%

• Growth Driver: The Increasing Cancer Incidence Is Fueling The Growth Of The Market Due To Its Rising Prevalence And Demand For Targeted Therapies

• Market Trend: Advancement Of Automated Radioligand Therapy Facilities To Meet Rising Demand

• North America was the largest region in 2024 and Asia-Pacific is the fastest growing region.

What Is Covered Under Radioligand Therapy Market?

Radioligand therapy (RLT) is an advanced form of targeted cancer treatment that links a radioactive isotope to a ligand designed to bind selectively to cancer cell receptors. After administration, it seeks out tumor cells and delivers precise radiation directly to them, minimizing damage to healthy tissue. Its targeted approach helps reduce side effects and improves outcomes, particularly in cases resistant to traditional treatments.

The main types of radioligands in radioligand therapy are alpha emitters, beta emitters, Auger emitters, and combined emissions. Alpha emitters release high-energy alpha particles over very short distances, just a few cell layers, making them highly effective for targeted cell destruction. These radioligands are designed to bind to specific molecular targets such as hormone receptors, growth factor receptors, antigen tumor markers, and others and can be administered through various routes of administration, including Intravenous (IV), intramuscular (IM), subcutaneous, and oral. Radioligand therapy is applied in treating a range of conditions such as oncological and cardiovascular disorders, neurological disorders, and infectious diseases, and is utilized across hospitals, diagnostic laboratories, research institutions, and home care setting.

Radioligand Therapy Market Size and growth rate 2025 to 2029: Graph

What Is The Radioligand Therapy Market Size 2025 And Growth Rate?

What Is The Radioligand Therapy Market Growth Forecast?

The radioligand therapy market size is expected to see rapid growth in the next few years. It will grow to $9.77 billion in 2029 at a compound annual growth rate (CAGR) of 10.2%. The growth in the forecast period can be attributed to rising investments by big pharma in oncology startups, increasing utilization of real-world evidence, growth in radiopharmaceutical and theranostics research, growing partnerships between academia and industry, and rising prevalence of rare and orphan cancers. Major trends in the forecast period include AI-driven radiopharmaceutical design, theranostics with dual imaging-therapy platforms, microfluidics-based radiotracer synthesis, next-generation alpha-emitting isotopes, and 3D-printed personalized dosimetry devices.

Book your 30 minutes free consultation with our research experts

What’s The Trade War Impact On Pharmaceuticals Industry?

The sudden escalation of U.S. tariffs and the consequent trade frictions in spring 2025 are severely impacting the pharmaceutical companies contend with tariffs on APIs, glass vials, and lab equipment inputs with few alternative sources. Generic drug makers, operating on razor-thin margins, are especially vulnerable, with some reducing production of low-profit medicines. Biotech firms face delays in clinical trials due to tariff-related shortages of specialized reagents. In response, the industry is expanding API production in India and Europe, increasing inventory stockpiles, and pushing for trade exemptions for essential medicines.

How Is The Radioligand Therapy Market Segmented?

1) By Type Of Radioligand: Alpha Emitters, Beta Emitters, Auger Emitters, Combined Emissions

2) By Molecular Target: Hormone Receptors, Growth Factor Receptors, Antigen Tumor Markers, Other Molecular Targets

3) By Route Of Administration: Intravenous (IV), Intramuscular (IM), Subcutaneous, Oral

4) By Application: Oncology, Cardiovascular Disorders, Neurological Disorders, Infectious Diseases

5) By End-User: Hospitals, Diagnostic Laboratories, Research Institutions, Home Care Settings

Subsegments:

1) By Alpha Emitters: Actinium-225 (Ac-225), Radium-223 (Ra-223), Astatine-211 (At-211), Bismuth-213 (Bi-213)

2) By Beta Emitters: Lutetium-177 (Lu-177), Iodine-131 (I-131), Yttrium-90 (Y-90), Samarium-153 (Sm-153)

3) By Auger Emitters: Iodine-125 (I-125), Indium-111 (In-111), Gallium-67 (Ga-67), Thallium-201 (Tl-201)

4) By Combined Emissions: Terbium-161 (Tb-161), Copper-67 (Cu-67), Rhenium-186 (Re-186), Lead-212 (Pb-212)

What Is Driving The Radioligand Therapy Market? The Increasing Cancer Incidence Is Fueling The Growth Of The Market Due To Its Rising Prevalence And Demand For Targeted Therapies

The increasing cancer incidence is expected to propel the growth of the radioligand therapy market going forward. Cancer is a disease marked by the uncontrolled growth of abnormal cells that can invade surrounding tissues and spread throughout the body. Cancer incidence is rising due to long-term exposure to environmental pollutants that damage DNA, disrupt cell function, and promote abnormal cell growth. Radioligand therapy treats cancer by directing radiation to tumor cells through ligands that bind to specific receptors, minimizing harm to healthy tissues and destroying cancer cells internally. For instance, in January 2022, according to the American Cancer Society, a US-based cancer awareness non-profit organization, in the US, an estimated 1.9 million new cancer cases and 609,360 cancer-related deaths are expected, reaching up to approximately 1,670 deaths on daily basis. Therefore, the increasing cancer incidence is driving the growth of the radioligand therapy industry.

Who Are The Major Players In The Global Radioligand Therapy Market?

Major companies operating in the radioligand therapy market are Bayer AG, Novartis AG, Eli Lilly and Company, Lantheus Holdings Inc., Curium LLC, Eckert & Ziegler Strahlen- und Medizintechnik AG, Molecular Partners AG, Telix Pharmaceuticals, Nanobiotix S.A., Mariana Oncology Inc., Artios Pharma Limited, AdvanCell Pty Ltd., Evergreen Theragnostics Inc., Fusion Pharmaceuticals Inc., RadioMedix Inc., Ariceum Therapeutics GmbH, Radiopharm Theranostics Limited, Convergent Therapeutics Inc., C-Ray Therapeutics Inc., OncoSil Medical Ltd.

What Are The Key Trends Of The Global Radioligand Therapy Market? Advancement Of Automated Radioligand Therapy Facilities To Meet Rising Demand

Major companies operating in the radioligand therapy market are focusing on developing advanced solutions, such as radioligand therapy facilities, to enhance production efficiency and maintain consistent quality and safety standards in the manufacturing and distribution of targeted cancer treatments. Radioligand therapy facilities are specialized centers designed to handle and deliver radioactive drugs for targeted cancer treatment using advanced imaging systems and radiation shielding while ensuring safety through trained personnel and strict protocols. For instance, in January 2024, Novartis AG, a Switzerland-based pharmaceutical company, announced the automation of its new large-scale radioligand therapy (RLT) production plant in Indiana. This plant received Food and Drug Administration (FDA) approval for commercial manufacturing. This 70,000-square-foot facility is the largest and most advanced Novartis site dedicated to RLT, designed for efficient, time-sensitive production, and includes plans for fully automated production lines, enabling substantial supply increases to meet growing patient demand in the US and Canada.

Need data on a specific region in this market?

Request Regional Data

What Are Latest Mergers And Acquisitions In The Radioligand Therapy Market? Eli Lilly and Company Acquired POINT Biopharma Global Inc. To Bolster Therapy Capabilities In Oncology

In December 2023, Eli Lilly and Company, a US-based pharmaceutical company, acquired POINT Biopharma Global Inc. for $1.4 billion. With this acquisition, Eli Lilly and Company aims to expand its oncology portfolio by integrating advanced radioligand therapy capabilities to enhance precision cancer treatment offerings. POINT Biopharma Global Inc. is a US-based pharmaceutical company that specializes in the development of radioligand treatments for cancer.

What Is The Regional Outlook For The Global Radioligand Therapy Market?

North America was the largest region in the radioligand therapy market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Radioligand Therapy Market?

The radioligand therapy market consists of revenues earned by entities by providing services such as targeted treatment services, diagnostic imaging, and clinical and infrastructure services. The market value includes the value of related goods sold by the service provider or included within the service offering. The radioligand therapy market also includes sales of somatostatin receptor ligands, radiolabeled bombesin analogs, radiolabeled monoclonal antibodies, and prostate-specific membrane antigen (PSMA)-targeted ligands. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What is the Market Assessment and Strategic Outlook for the Radioligand Therapy Industry?

The radioligand therapy market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the radioligand therapy industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.

Author : Abhilash Pyata

Radioligand Therapy Market Report Forecast Analysis

Report Attribute	Details
Market Size Value In 2025	$6.64 billion
Revenue Forecast In 2034	$9.77 billion
Growth Rate	CAGR of 10.2% from 2025 to 2034
Base Year For Estimation	2024
Actual Estimates/Historical Data	2019-2024
Forecast Period	2025 - 2029 - 2034
Market Representation	Revenue in USD Billion and CAGR from 2025 to 2034
Segments Covered	Type Of Radioligand, Molecular Target, Route Of Administration, Application, End-User
Regional Scope	Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Country Scope	The countries covered in the report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain. Additional countries that can be covered in the report are Bangladesh, Thailand, Vietnam, Malaysia, Singapore, Philippines, Hong Kong, New Zealand, Mexico, Chile, Argentina, Colombia, Peru, Austria, Belgium, Denmark, Finland, Ireland, Netherlands, Norway, Portugal, Sweden, Switzerland, Czech Republic, Poland, Romania, Ukraine, Saudi Arabia, Israel, Iran, Turkey, UAE, Egypt, Nigeria, South Africa.
Key Companies Profiled	Bayer AG, Novartis AG, Eli Lilly and Company, Lantheus Holdings Inc., Curium LLC, Eckert & Ziegler Strahlen- und Medizintechnik AG, Molecular Partners AG, Telix Pharmaceuticals, Nanobiotix S.A., Mariana Oncology Inc., Artios Pharma Limited, AdvanCell Pty Ltd., Evergreen Theragnostics Inc., Fusion Pharmaceuticals Inc., RadioMedix Inc., Ariceum Therapeutics GmbH, Radiopharm Theranostics Limited, Convergent Therapeutics Inc., C-Ray Therapeutics Inc., OncoSil Medical Ltd.
Customization Scope	Request for Sample
Pricing And Purchase Options	Explore Purchase Options

1. Executive Summary

2. Radioligand Therapy Market Characteristics

3. Radioligand Therapy Market Trends And Strategies

4. Radioligand Therapy Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

4.1. Supply Chain Impact from Tariff War & Trade Protectionism

5. Global Radioligand Therapy Growth Analysis And Strategic Analysis Framework

5.1. Global Radioligand Therapy PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)

5.2. Analysis Of End Use Industries

5.3. Global Radioligand Therapy Market Growth Rate Analysis

5.4. Global Radioligand Therapy Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)

5.5. Global Radioligand Therapy Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)

5.6. Global Radioligand Therapy Total Addressable Market (TAM)

6. Radioligand Therapy Market Segmentation

6.1. Global Radioligand Therapy Market, Segmentation By Type Of Radioligand, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Alpha Emitters

Beta Emitters

Auger Emitters

Combined Emissions

6.2. Global Radioligand Therapy Market, Segmentation By Molecular Target, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Hormone Receptors

Growth Factor Receptors

Antigen Tumor Markers

Other Molecular Targets

6.3. Global Radioligand Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Intravenous (IV)

Intramuscular (IM)

Subcutaneous

Oral

6.4. Global Radioligand Therapy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Oncology

Cardiovascular Disorders

Neurological Disorders

Infectious Diseases

6.5. Global Radioligand Therapy Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Hospitals

Diagnostic Laboratories

Research Institutions

Home Care Settings

6.6. Global Radioligand Therapy Market, Sub-Segmentation Of Alpha Emitters, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Actinium-225 (Ac-225)

Radium-223 (Ra-223)

Astatine-211 (At-211)

Bismuth-213 (Bi-213)

6.7. Global Radioligand Therapy Market, Sub-Segmentation Of Beta Emitters, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Lutetium-177 (Lu-177)

Iodine-131 (I-131)

Yttrium-90 (Y-90)

Samarium-153 (Sm-153)

6.8. Global Radioligand Therapy Market, Sub-Segmentation Of Auger Emitters, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Iodine-125 (I-125)

Indium-111 (In-111)

Gallium-67 (Ga-67)

Thallium-201 (Tl-201)

6.9. Global Radioligand Therapy Market, Sub-Segmentation Of Combined Emissions, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Terbium-161 (Tb-161)

Copper-67 (Cu-67)

Rhenium-186 (Re-186)

Lead-212 (Pb-212)

7. Radioligand Therapy Market Regional And Country Analysis

7.1. Global Radioligand Therapy Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

7.2. Global Radioligand Therapy Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Radioligand Therapy Market

8.1. Asia-Pacific Radioligand Therapy Market Overview

Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

8.2. Asia-Pacific Radioligand Therapy Market, Segmentation By Type Of Radioligand, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8.3. Asia-Pacific Radioligand Therapy Market, Segmentation By Molecular Target, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8.4. Asia-Pacific Radioligand Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Radioligand Therapy Market

9.1. China Radioligand Therapy Market Overview

9.2. China Radioligand Therapy Market, Segmentation By Type Of Radioligand, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

9.3. China Radioligand Therapy Market, Segmentation By Molecular Target, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

9.4. China Radioligand Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Radioligand Therapy Market

10.1. India Radioligand Therapy Market, Segmentation By Type Of Radioligand, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

10.2. India Radioligand Therapy Market, Segmentation By Molecular Target, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

10.3. India Radioligand Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Radioligand Therapy Market

11.1. Japan Radioligand Therapy Market Overview

11.2. Japan Radioligand Therapy Market, Segmentation By Type Of Radioligand, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11.3. Japan Radioligand Therapy Market, Segmentation By Molecular Target, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11.4. Japan Radioligand Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Radioligand Therapy Market

12.1. Australia Radioligand Therapy Market, Segmentation By Type Of Radioligand, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12.2. Australia Radioligand Therapy Market, Segmentation By Molecular Target, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12.3. Australia Radioligand Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Radioligand Therapy Market

13.1. Indonesia Radioligand Therapy Market, Segmentation By Type Of Radioligand, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13.2. Indonesia Radioligand Therapy Market, Segmentation By Molecular Target, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13.3. Indonesia Radioligand Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Radioligand Therapy Market

14.1. South Korea Radioligand Therapy Market Overview

14.2. South Korea Radioligand Therapy Market, Segmentation By Type Of Radioligand, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14.3. South Korea Radioligand Therapy Market, Segmentation By Molecular Target, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14.4. South Korea Radioligand Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Radioligand Therapy Market

15.1. Western Europe Radioligand Therapy Market Overview

15.2. Western Europe Radioligand Therapy Market, Segmentation By Type Of Radioligand, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15.3. Western Europe Radioligand Therapy Market, Segmentation By Molecular Target, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15.4. Western Europe Radioligand Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Radioligand Therapy Market

16.1. UK Radioligand Therapy Market, Segmentation By Type Of Radioligand, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16.2. UK Radioligand Therapy Market, Segmentation By Molecular Target, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16.3. UK Radioligand Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Radioligand Therapy Market

17.1. Germany Radioligand Therapy Market, Segmentation By Type Of Radioligand, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17.2. Germany Radioligand Therapy Market, Segmentation By Molecular Target, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17.3. Germany Radioligand Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Radioligand Therapy Market

18.1. France Radioligand Therapy Market, Segmentation By Type Of Radioligand, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18.2. France Radioligand Therapy Market, Segmentation By Molecular Target, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18.3. France Radioligand Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Radioligand Therapy Market

19.1. Italy Radioligand Therapy Market, Segmentation By Type Of Radioligand, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19.2. Italy Radioligand Therapy Market, Segmentation By Molecular Target, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19.3. Italy Radioligand Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Radioligand Therapy Market

20.1. Spain Radioligand Therapy Market, Segmentation By Type Of Radioligand, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20.2. Spain Radioligand Therapy Market, Segmentation By Molecular Target, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20.3. Spain Radioligand Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Radioligand Therapy Market

21.1. Eastern Europe Radioligand Therapy Market Overview

21.2. Eastern Europe Radioligand Therapy Market, Segmentation By Type Of Radioligand, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21.3. Eastern Europe Radioligand Therapy Market, Segmentation By Molecular Target, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21.4. Eastern Europe Radioligand Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Radioligand Therapy Market

22.1. Russia Radioligand Therapy Market, Segmentation By Type Of Radioligand, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22.2. Russia Radioligand Therapy Market, Segmentation By Molecular Target, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22.3. Russia Radioligand Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Radioligand Therapy Market

23.1. North America Radioligand Therapy Market Overview

23.2. North America Radioligand Therapy Market, Segmentation By Type Of Radioligand, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23.3. North America Radioligand Therapy Market, Segmentation By Molecular Target, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23.4. North America Radioligand Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Radioligand Therapy Market

24.1. USA Radioligand Therapy Market Overview

24.2. USA Radioligand Therapy Market, Segmentation By Type Of Radioligand, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24.3. USA Radioligand Therapy Market, Segmentation By Molecular Target, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24.4. USA Radioligand Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Radioligand Therapy Market

25.1. Canada Radioligand Therapy Market Overview

25.2. Canada Radioligand Therapy Market, Segmentation By Type Of Radioligand, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25.3. Canada Radioligand Therapy Market, Segmentation By Molecular Target, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25.4. Canada Radioligand Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Radioligand Therapy Market

26.1. South America Radioligand Therapy Market Overview

26.2. South America Radioligand Therapy Market, Segmentation By Type Of Radioligand, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26.3. South America Radioligand Therapy Market, Segmentation By Molecular Target, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26.4. South America Radioligand Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Radioligand Therapy Market

27.1. Brazil Radioligand Therapy Market, Segmentation By Type Of Radioligand, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27.2. Brazil Radioligand Therapy Market, Segmentation By Molecular Target, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27.3. Brazil Radioligand Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Radioligand Therapy Market

28.1. Middle East Radioligand Therapy Market Overview

28.2. Middle East Radioligand Therapy Market, Segmentation By Type Of Radioligand, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28.3. Middle East Radioligand Therapy Market, Segmentation By Molecular Target, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28.4. Middle East Radioligand Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Radioligand Therapy Market

29.1. Africa Radioligand Therapy Market Overview

29.2. Africa Radioligand Therapy Market, Segmentation By Type Of Radioligand, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29.3. Africa Radioligand Therapy Market, Segmentation By Molecular Target, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29.4. Africa Radioligand Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Radioligand Therapy Market Competitive Landscape And Company Profiles

30.1. Radioligand Therapy Market Competitive Landscape

30.2. Radioligand Therapy Market Company Profiles

30.2.1. Bayer AG Overview, Products and Services, Strategy and Financial Analysis

30.2.2. Novartis AG Overview, Products and Services, Strategy and Financial Analysis

30.2.3. Eli Lilly and Company Overview, Products and Services, Strategy and Financial Analysis

30.2.4. Lantheus Holdings Inc. Overview, Products and Services, Strategy and Financial Analysis

30.2.5. Curium LLC Overview, Products and Services, Strategy and Financial Analysis

31. Radioligand Therapy Market Other Major And Innovative Companies

31.1. Eckert & Ziegler Strahlen- und Medizintechnik AG

31.2. Molecular Partners AG

31.3. Telix Pharmaceuticals

31.4. Nanobiotix S.A.

31.5. Mariana Oncology Inc.

31.6. Artios Pharma Limited

31.7. AdvanCell Pty Ltd.

31.8. Evergreen Theragnostics Inc.

31.9. Fusion Pharmaceuticals Inc.

31.10. RadioMedix Inc.

31.11. Ariceum Therapeutics GmbH

31.12. Radiopharm Theranostics Limited

31.13. Convergent Therapeutics Inc.

31.14. C-Ray Therapeutics Inc.

31.15. OncoSil Medical Ltd.

32. Global Radioligand Therapy Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Radioligand Therapy Market

34. Recent Developments In The Radioligand Therapy Market

35. Radioligand Therapy Market High Potential Countries, Segments and Strategies

35.1 Radioligand Therapy Market In 2029 - Countries Offering Most New Opportunities

35.2 Radioligand Therapy Market In 2029 - Segments Offering Most New Opportunities

35.3 Radioligand Therapy Market In 2029 - Growth Strategies

35.3.1 Market Trend Based Strategies

35.3.2 Competitor Strategies

36. Appendix

36.1. Abbreviations

36.2. Currencies

36.3. Historic And Forecast Inflation Rates

36.4. Research Inquiries

36.5. The Business Research Company

36.6. Copyright And Disclaimer

List Of Tables

Table 1: Global Historic Market Growth, 2019-2024, $ Billion

Table 2: Global Forecast Market Growth, 2024-2029F, 2034F, $ Billion

Table 3: Global Radioligand Therapy Market, Segmentation By Type Of Radioligand, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 4: Global Radioligand Therapy Market, Segmentation By Molecular Target, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 5: Global Radioligand Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 6: Global Radioligand Therapy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 7: Global Radioligand Therapy Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 8: Global Radioligand Therapy Market, Sub-Segmentation Of Alpha Emitters, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 9: Global Radioligand Therapy Market, Sub-Segmentation Of Beta Emitters, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 10: Global Radioligand Therapy Market, Sub-Segmentation Of Auger Emitters, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 11: Global Radioligand Therapy Market, Sub-Segmentation Of Combined Emissions, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 12: Global Radioligand Therapy Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 13: Global Radioligand Therapy Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 14: Asia-Pacific, Radioligand Therapy Market, Segmentation By Type Of Radioligand, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 15: Asia-Pacific, Radioligand Therapy Market, Segmentation By Molecular Target, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 16: Asia-Pacific, Radioligand Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 17: China, Radioligand Therapy Market, Segmentation By Type Of Radioligand, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 18: China, Radioligand Therapy Market, Segmentation By Molecular Target, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 19: China, Radioligand Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 20: India, Radioligand Therapy Market, Segmentation By Type Of Radioligand, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 21: India, Radioligand Therapy Market, Segmentation By Molecular Target, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 22: India, Radioligand Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 23: Japan, Radioligand Therapy Market, Segmentation By Type Of Radioligand, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 24: Japan, Radioligand Therapy Market, Segmentation By Molecular Target, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 25: Japan, Radioligand Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 26: Australia, Radioligand Therapy Market, Segmentation By Type Of Radioligand, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 27: Australia, Radioligand Therapy Market, Segmentation By Molecular Target, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 28: Australia, Radioligand Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 29: Indonesia, Radioligand Therapy Market, Segmentation By Type Of Radioligand, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 30: Indonesia, Radioligand Therapy Market, Segmentation By Molecular Target, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 31: Indonesia, Radioligand Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 32: South Korea, Radioligand Therapy Market, Segmentation By Type Of Radioligand, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 33: South Korea, Radioligand Therapy Market, Segmentation By Molecular Target, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 34: South Korea, Radioligand Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 35: Western Europe, Radioligand Therapy Market, Segmentation By Type Of Radioligand, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 36: Western Europe, Radioligand Therapy Market, Segmentation By Molecular Target, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 37: Western Europe, Radioligand Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 38: UK, Radioligand Therapy Market, Segmentation By Type Of Radioligand, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 39: UK, Radioligand Therapy Market, Segmentation By Molecular Target, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 40: UK, Radioligand Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 41: Germany, Radioligand Therapy Market, Segmentation By Type Of Radioligand, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 42: Germany, Radioligand Therapy Market, Segmentation By Molecular Target, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 43: Germany, Radioligand Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 44: France, Radioligand Therapy Market, Segmentation By Type Of Radioligand, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 45: France, Radioligand Therapy Market, Segmentation By Molecular Target, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 46: France, Radioligand Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 47: Italy, Radioligand Therapy Market, Segmentation By Type Of Radioligand, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 48: Italy, Radioligand Therapy Market, Segmentation By Molecular Target, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 49: Italy, Radioligand Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 50: Spain, Radioligand Therapy Market, Segmentation By Type Of Radioligand, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 51: Spain, Radioligand Therapy Market, Segmentation By Molecular Target, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 52: Spain, Radioligand Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 53: Eastern Europe, Radioligand Therapy Market, Segmentation By Type Of Radioligand, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 54: Eastern Europe, Radioligand Therapy Market, Segmentation By Molecular Target, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 55: Eastern Europe, Radioligand Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 56: Russia, Radioligand Therapy Market, Segmentation By Type Of Radioligand, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 57: Russia, Radioligand Therapy Market, Segmentation By Molecular Target, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 58: Russia, Radioligand Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 59: North America, Radioligand Therapy Market, Segmentation By Type Of Radioligand, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 60: North America, Radioligand Therapy Market, Segmentation By Molecular Target, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 61: North America, Radioligand Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 62: USA, Radioligand Therapy Market, Segmentation By Type Of Radioligand, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 63: USA, Radioligand Therapy Market, Segmentation By Molecular Target, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 64: USA, Radioligand Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 65: Canada, Radioligand Therapy Market, Segmentation By Type Of Radioligand, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 66: Canada, Radioligand Therapy Market, Segmentation By Molecular Target, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 67: Canada, Radioligand Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 68: South America, Radioligand Therapy Market, Segmentation By Type Of Radioligand, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 69: South America, Radioligand Therapy Market, Segmentation By Molecular Target, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 70: South America, Radioligand Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 71: Brazil, Radioligand Therapy Market, Segmentation By Type Of Radioligand, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 72: Brazil, Radioligand Therapy Market, Segmentation By Molecular Target, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 73: Brazil, Radioligand Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 74: Middle East, Radioligand Therapy Market, Segmentation By Type Of Radioligand, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 75: Middle East, Radioligand Therapy Market, Segmentation By Molecular Target, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 76: Middle East, Radioligand Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 77: Africa, Radioligand Therapy Market, Segmentation By Type Of Radioligand, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 78: Africa, Radioligand Therapy Market, Segmentation By Molecular Target, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 79: Africa, Radioligand Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 80: Bayer AG Financial Performance

Table 81: Novartis AG Financial Performance

Table 82: Eli Lilly and Company Financial Performance

Table 83: Lantheus Holdings Inc. Financial Performance

Table 84: Curium LLC Financial Performance

List Of Figures

Figure 1: Global Historic Market Growth, 2019-2024, $ Billion

Figure 2: Global Forecast Market Growth, 2024-2029F, 2034F, $ Billion

Figure 3: Global Radioligand Therapy Market, Segmentation By Type Of Radioligand, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 4: Global Radioligand Therapy Market, Segmentation By Molecular Target, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 5: Global Radioligand Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 6: Global Radioligand Therapy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 7: Global Radioligand Therapy Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 8: Global Radioligand Therapy Market, Sub-Segmentation Of Alpha Emitters, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 9: Global Radioligand Therapy Market, Sub-Segmentation Of Beta Emitters, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 10: Global Radioligand Therapy Market, Sub-Segmentation Of Auger Emitters, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 11: Global Radioligand Therapy Market, Sub-Segmentation Of Combined Emissions, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 12: Global Radioligand Therapy Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 13: Global Radioligand Therapy Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 14: Asia-Pacific, Radioligand Therapy Market, Segmentation By Type Of Radioligand, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 15: Asia-Pacific, Radioligand Therapy Market, Segmentation By Molecular Target, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 16: Asia-Pacific, Radioligand Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 17: China, Radioligand Therapy Market, Segmentation By Type Of Radioligand, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 18: China, Radioligand Therapy Market, Segmentation By Molecular Target, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 19: China, Radioligand Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 20: India, Radioligand Therapy Market, Segmentation By Type Of Radioligand, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 21: India, Radioligand Therapy Market, Segmentation By Molecular Target, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 22: India, Radioligand Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 23: Japan, Radioligand Therapy Market, Segmentation By Type Of Radioligand, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 24: Japan, Radioligand Therapy Market, Segmentation By Molecular Target, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 25: Japan, Radioligand Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 26: Australia, Radioligand Therapy Market, Segmentation By Type Of Radioligand, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 27: Australia, Radioligand Therapy Market, Segmentation By Molecular Target, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 28: Australia, Radioligand Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 29: Indonesia, Radioligand Therapy Market, Segmentation By Type Of Radioligand, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 30: Indonesia, Radioligand Therapy Market, Segmentation By Molecular Target, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 31: Indonesia, Radioligand Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 32: South Korea, Radioligand Therapy Market, Segmentation By Type Of Radioligand, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 33: South Korea, Radioligand Therapy Market, Segmentation By Molecular Target, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 34: South Korea, Radioligand Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 35: Western Europe, Radioligand Therapy Market, Segmentation By Type Of Radioligand, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 36: Western Europe, Radioligand Therapy Market, Segmentation By Molecular Target, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 37: Western Europe, Radioligand Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 38: UK, Radioligand Therapy Market, Segmentation By Type Of Radioligand, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 39: UK, Radioligand Therapy Market, Segmentation By Molecular Target, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 40: UK, Radioligand Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 41: Germany, Radioligand Therapy Market, Segmentation By Type Of Radioligand, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 42: Germany, Radioligand Therapy Market, Segmentation By Molecular Target, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 43: Germany, Radioligand Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 44: France, Radioligand Therapy Market, Segmentation By Type Of Radioligand, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 45: France, Radioligand Therapy Market, Segmentation By Molecular Target, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 46: France, Radioligand Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 47: Italy, Radioligand Therapy Market, Segmentation By Type Of Radioligand, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 48: Italy, Radioligand Therapy Market, Segmentation By Molecular Target, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 49: Italy, Radioligand Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 50: Spain, Radioligand Therapy Market, Segmentation By Type Of Radioligand, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 51: Spain, Radioligand Therapy Market, Segmentation By Molecular Target, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 52: Spain, Radioligand Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 53: Eastern Europe, Radioligand Therapy Market, Segmentation By Type Of Radioligand, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 54: Eastern Europe, Radioligand Therapy Market, Segmentation By Molecular Target, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 55: Eastern Europe, Radioligand Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 56: Russia, Radioligand Therapy Market, Segmentation By Type Of Radioligand, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 57: Russia, Radioligand Therapy Market, Segmentation By Molecular Target, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 58: Russia, Radioligand Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 59: North America, Radioligand Therapy Market, Segmentation By Type Of Radioligand, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 60: North America, Radioligand Therapy Market, Segmentation By Molecular Target, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 61: North America, Radioligand Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 62: USA, Radioligand Therapy Market, Segmentation By Type Of Radioligand, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 63: USA, Radioligand Therapy Market, Segmentation By Molecular Target, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 64: USA, Radioligand Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 65: Canada, Radioligand Therapy Market, Segmentation By Type Of Radioligand, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 66: Canada, Radioligand Therapy Market, Segmentation By Molecular Target, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 67: Canada, Radioligand Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 68: South America, Radioligand Therapy Market, Segmentation By Type Of Radioligand, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 69: South America, Radioligand Therapy Market, Segmentation By Molecular Target, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 70: South America, Radioligand Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 71: Brazil, Radioligand Therapy Market, Segmentation By Type Of Radioligand, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 72: Brazil, Radioligand Therapy Market, Segmentation By Molecular Target, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 73: Brazil, Radioligand Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 74: Middle East, Radioligand Therapy Market, Segmentation By Type Of Radioligand, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 75: Middle East, Radioligand Therapy Market, Segmentation By Molecular Target, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 76: Middle East, Radioligand Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 77: Africa, Radioligand Therapy Market, Segmentation By Type Of Radioligand, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 78: Africa, Radioligand Therapy Market, Segmentation By Molecular Target, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 79: Africa, Radioligand Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 80: Bayer AG Financial Performance

Figure 81: Novartis AG Financial Performance

Figure 82: Eli Lilly and Company Financial Performance

Figure 83: Lantheus Holdings Inc. Financial Performance

Figure 84: Curium LLC Financial Performance

Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Market Forecast 2025–2034: Trends Reshaping Demand, Investment, and Innovation

Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Projected to Reach $47.74 Billion by 2029 at a CAGR of 30.7%

$8.21 Billion Forecast for Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market by 2029, Backed by Demand and Innovation

Fentanyl Market Forecast Reaching $22.03 Billion by 2029 at 6.5% CAGR

A 2025 analysis offering size estimates, growth trends and technological innovations in the live cell imaging microscopes market.

A 2025 market overview covering growth forecasts, treatment landscape, and key stakeholders in the isovaleric acidemia treatment market.

Discover key trends and market dynamics in the Mycobacterium Tuberculosis Market with 2025 insights from The Business Research Company.

Discover key trends and market dynamics in the Smoking Cessation & Nicotine De-addiction Products Market with 2025 insights from The Business Research Company.

Real Estate Rental Global Market Report 2025 – By Type (Residential Buildings And Dwellings Rental Services, Non-Residential Buildings Rental Services, Mini warehouses And Self-Storage Units Rental Services, Other Rental...

Financial Accounting Advisory Services Global Market Report 2025 – By Type (Accounting Change Services, Buy-Side Support, Bankruptcy Services, IPO Advisory Services, Financial Reporting Issue And Restatement Services, Te...

Real Estate Agency and Brokerage Global Market Report 2025 – By Type (Residential Buildings And Dwellings Brokers, Non-Residential Buildings Brokers, Mini warehouses And Self-Storage Units Brokers, Other Brokers), By Mod...

Residential Real Estate Global Market Report 2025 – By Type (Apartments, Condominiums, Landed Houses, Villas), By Pricing (Affordable, Mid-Range, Luxury), By Size (Less Than 50 Square Meters, 51 To 80 Square Meters, 81 T...

Financial Advisory Global Market Report 2025 – By Type (Corporate Finance, Accounting Advisory, Tax Advisory, Transaction Services, Risk Management, Other Types), By Organization Size (Large Enterprises, Small And Medium...

Operations Advisory Global Market Report 2025 – By Product Type (Financial Advisory, Technology Advisory, Strategy Advisory, HR Advisory, Manufacturing), By Size (Large Enterprises, Small And Medium Enterprises), By Vert...

Real Estate Software Global Market Report 2025 – By Product (Enterprise Resource Planning (ERP), Property Management System (PMS), Customer Relationship Management (CRM)), By Deployment Type (Cloud, On-Premise), By Appli...

Frequently Asked Questions

What is the definition of the Radioligand Therapy market?

How will the Radioligand Therapy market drivers and restraints affect the market dynamics? What forces will shape the Radioligand Therapy industry going forward?

The market major growth driver - The Increasing Cancer Incidence Is Fueling The Growth Of The Market Due To Its Rising Prevalence And Demand For Targeted Therapies. For further insights on this market, request a sample here

What is the forecast market size or the forecast market value of the Radioligand Therapy market?

The radioligand therapy market size has grown rapidly in recent years. It will grow from $6.01 billion in 2024 to $6.64 billion in 2025 at a compound annual growth rate (CAGR) of 10.5%. The growth in the historic period can be attributed to the rise in liquid biopsy usage, the emergence of tumor-agnostic therapies, the integration of artificial intelligence in oncology, the growing pipeline of bispecific antibodies, and the increase in government funding for cancer. The radioligand therapy market size is expected to see rapid growth in the next few years. It will grow to $9.77 billion in 2029 at a compound annual growth rate (CAGR) of 10.2%. The growth in the forecast period can be attributed to rising investments by big pharma in oncology startups, increasing utilization of real-world evidence, growth in radiopharmaceutical and theranostics research, growing partnerships between academia and industry, and rising prevalence of rare and orphan cancers. Major trends in the forecast period include AI-driven radiopharmaceutical design, theranostics with dual imaging-therapy platforms, microfluidics-based radiotracer synthesis, next-generation alpha-emitting isotopes, and 3D-printed personalized dosimetry devices. For further insights on this market, request a sample here

How is the Radioligand Therapy market segmented?

The radioligand therapy market covered in this report is segmented
1) By Type Of Radioligand: Alpha Emitters, Beta Emitters, Auger Emitters, Combined Emissions
2) By Molecular Target: Hormone Receptors, Growth Factor Receptors, Antigen Tumor Markers, Other Molecular Targets
3) By Route Of Administration: Intravenous (IV), Intramuscular (IM), Subcutaneous, Oral
4) By Application: Oncology, Cardiovascular Disorders, Neurological Disorders, Infectious Diseases
5) By End-User: Hospitals, Diagnostic Laboratories, Research Institutions, Home Care Settings Subsegments:
1) By Alpha Emitters: Actinium-225 (Ac-225), Radium-223 (Ra-223), Astatine-211 (At-211), Bismuth-213 (Bi-213)
2) By Beta Emitters: Lutetium-177 (Lu-177), Iodine-131 (I-131), Yttrium-90 (Y-90), Samarium-153 (Sm-153)
3) By Auger Emitters: Iodine-125 (I-125), Indium-111 (In-111), Gallium-67 (Ga-67), Thallium-201 (Tl-201)
4) By Combined Emissions: Terbium-161 (Tb-161), Copper-67 (Cu-67), Rhenium-186 (Re-186), Lead-212 (Pb-212) For further insights on this market, request a sample here

Which region has the largest share of the Radioligand Therapy market? What are the other regions covered in the report?

North America was the largest region in the radioligand therapy market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the radioligand therapy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. For further insights on this market, request a sample here.

Who are the major players in the Radioligand Therapy market?

What are the key trends in the Radioligand Therapy market?

Major trends in this market include Advancement Of Automated Radioligand Therapy Facilities To Meet Rising Demand. For further insights on this market, request a sample here.